These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 32074486)

  • 1. Evaluation of long-term efficacy, safety, and reasons for discontinuation of dupilumab for moderate to severe atopic dermatitis in clinical practice: A retrospective cohort study.
    Jo CE; Georgakopoulos JR; Ladda M; Ighani A; Mufti A; Drucker AM; Piguet V; Yeung J
    J Am Acad Dermatol; 2020 Jun; 82(6):1530-1532. PubMed ID: 32074486
    [No Abstract]   [Full Text] [Related]  

  • 2. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study.
    Deleuran M; Thaçi D; Beck LA; de Bruin-Weller M; Blauvelt A; Forman S; Bissonnette R; Reich K; Soong W; Hussain I; Foley P; Hide M; Bouaziz JD; Gelfand JM; Sher L; Schuttelaar MLA; Wang C; Chen Z; Akinlade B; Gadkari A; Eckert L; Davis JD; Rajadhyaksha M; Staudinger H; Graham NMH; Pirozzi G; Ardeleanu M
    J Am Acad Dermatol; 2020 Feb; 82(2):377-388. PubMed ID: 31374300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records.
    Wang C; Kraus CN; Patel KG; Ganesan AK; Grando SA
    Int J Dermatol; 2020 Feb; 59(2):253-256. PubMed ID: 31286499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-Term Evaluation of the Real-World Efficacy and Safety of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis: A Canadian Multicenter Retrospective Cohort Study [Formula: see text].
    Jo CE; Georgakopoulos JR; Ladda M; Ighani A; Mufti A; Drucker AM; Piguet V; Yeung J
    J Cutan Med Surg; 2020; 24(5):468-473. PubMed ID: 32442020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of dupilumab in atopic dermatitis in elderly patients: a retrospective study.
    Napolitano M; Fabbrocini G; Scalvenzi M; Blasio C; Stingeni L; Patruno C
    Clin Exp Dermatol; 2020 Oct; 45(7):888-890. PubMed ID: 32365237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-life long-term efficacy of dupilumab in adults with moderate to severe atopic dermatitis: Results of a cohort study.
    Guédon C; Tauber M; Linder C; Paul C; Shourick J
    Ann Dermatol Venereol; 2023 Sep; 150(3):215-216. PubMed ID: 37598014
    [No Abstract]   [Full Text] [Related]  

  • 7. Fifty-two week follow-up safety and effectiveness results of dupilumab treatment of moderate-to-severe atopic dermatitis from a retrospective, multicentric series.
    Ruiz-Villaverde R; Dominguez-Cruz J; Armario-Hita JC; Martinez-Pilar L; Alcantara-Luna S; Pereyra-Rodriguez JJ
    Dermatol Ther; 2019 Jul; 32(4):e12931. PubMed ID: 30980485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study.
    Johansson EK; Ivert LU; Bradley B; Lundqvist M; Bradley M
    BMC Dermatol; 2020 Sep; 20(1):8. PubMed ID: 32962676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry.
    Bosma AL; de Wijs LEM; Hof MH; van Nieuwenhuizen BR; Gerbens LAA; Middelkamp-Hup MA; Hijnen D; Spuls PI
    J Am Acad Dermatol; 2020 Nov; 83(5):1375-1384. PubMed ID: 32485210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis of a case series of adult patients with severe atopic dermatitis treated with dupilumab in Argentina].
    Máspero J; Angles MV; Ardusso L; Brancciforte M; Castro C; Cruz Iturrieta C; Chouela E; De Gennaro MS; Fernández Bussy R; Galimberti ML; Galimberti RL; Gattolin G; Luna PC; Magariños G; Marini MG; Maskin M; Plafnik R; Raimondo N; Russo JP; Sevinsky L; Stringa MF
    Rev Fac Cien Med Univ Nac Cordoba; 2020 Jun; 77(2):94-99. PubMed ID: 32558511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis.
    Liberman P; Shifera AS; Berkenstock M
    Cornea; 2020 Jun; 39(6):784-786. PubMed ID: 31985517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index.
    Ariëns LFM; Gadkari A; van Os-Medendorp H; Ayyagari R; Terasawa E; Kuznik A; Chen Z; Bégo-Le Bagousse G; Lu Y; Rizova E; Graham NMH; Pirozzi G; De Bruin-Weller M; Eckert L
    Acta Derm Venereol; 2019 Sep; 99(10):851-857. PubMed ID: 31099402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dupilumab Efficacy and Safety in Adolescents with Moderate-to-Severe Atopic Dermatitis: A Case Series.
    Mareschal A; Puzenat E; Aubin F
    Acta Derm Venereol; 2020 Jan; 100(1):adv00014. PubMed ID: 31709451
    [No Abstract]   [Full Text] [Related]  

  • 14. Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry.
    Ariëns LFM; van der Schaft J; Spekhorst LS; Bakker DS; Romeijn GLE; Kouwenhoven TA; Kamsteeg M; Voorberg AN; Oosting AJ; de Ridder I; Sloeserwij A; Haeck I; Thijs JL; Schuttelaar MLA; de Bruin-Weller MS
    J Am Acad Dermatol; 2021 Apr; 84(4):1000-1009. PubMed ID: 32946967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of moderate-to-severe atopic dermatitis with dupilumab in real clinical practice: a multicentre, retrospective case series.
    Armario-Hita JC; Pereyra-Rodriguez J; Silvestre JF; Ruiz-Villaverde R; Valero A; Izu-Belloso R; Jáuregui-Presa I; Curto-Barredo L; Figueras-Nart I; Herranz-Pinto P; Herraez-Herrera L; Ortiz-de-Frutos FJ; Martinez-Pilar L; Sastre J; Serra-Baldrich E
    Br J Dermatol; 2019 Nov; 181(5):1072-1074. PubMed ID: 31021399
    [No Abstract]   [Full Text] [Related]  

  • 16. Reasons for discontinuation of dupilumab in adult atopic dermatitis in clinical practice.
    Marniquet ME; Seneschal J; Darrigade AS; Staumont-Sallé D; Jachiet M; Nosbaum A; Tauber M; Abasq C; Ferrier Le Bouedec MC; Droitcourt C; Aubert H; Bernier C; Soria A; Raison-Peyron N; Tétart F; Aubin F; Viguier M; Valois A; Kupfer-Bessaguet I; Goronflot T; Barbarot S;
    Br J Dermatol; 2022 Apr; 186(4):733-735. PubMed ID: 34748654
    [No Abstract]   [Full Text] [Related]  

  • 17. COVID-19 Does Not Influence the Time to Relapse Following Dupilumab Discontinuation in Patients With Moderate-to-Severe Atopic Dermatitis.
    Sun XK
    Dermatitis; 2024; 35(5):523-524. PubMed ID: 38156808
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2).
    Thaçi D; L Simpson E; Deleuran M; Kataoka Y; Chen Z; Gadkari A; Eckert L; Akinlade B; Graham NMH; Pirozzi G; Ardeleanu M
    J Dermatol Sci; 2019 May; 94(2):266-275. PubMed ID: 31109652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of abrocitinib for the treatment of moderate-to-severe atopic dermatitis in patients switched from dupilumab and/or tralokinumab: A real-world retrospective study.
    Keow S; Abu-Hilal M
    J Am Acad Dermatol; 2024 Oct; 91(4):734-735. PubMed ID: 38857764
    [No Abstract]   [Full Text] [Related]  

  • 20. Rapid disappearance of both severe atopic dermatitis and cold urticaria following dupilumab treatment.
    Ferrucci S; Benzecry V; Berti E; Asero R
    Clin Exp Dermatol; 2020 Apr; 45(3):345-346. PubMed ID: 31437869
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.